Treatment personalization in gastrointestinal neuroendocrine tumors.
Biomarkers, Tumor
Clinical Decision-Making
Combined Modality Therapy
Diagnostic Imaging
/ methods
Disease Management
Disease Susceptibility
Gastrointestinal Neoplasms
/ diagnosis
Humans
Multimodal Imaging
/ methods
Neuroendocrine Tumors
/ diagnosis
Precision Medicine
/ methods
Prognosis
Treatment Outcome
GEP-NENs
Immunotherapy
NETs
PRRT
SSAs
Targeted therapies
Journal
Current treatment options in oncology
ISSN: 1534-6277
Titre abrégé: Curr Treat Options Oncol
Pays: United States
ID NLM: 100900946
Informations de publication
Date de publication:
27 02 2021
27 02 2021
Historique:
accepted:
18
01
2021
entrez:
28
2
2021
pubmed:
1
3
2021
medline:
11
1
2022
Statut:
epublish
Résumé
The clinical scenario of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) is continuously changing due to significant improvements in the definition of their molecular landscapes and the introduction of innovative therapeutic approaches. Many efforts are currently employed in the integration of the genetics/epigenetics and clinical information. This is leading to an improvement of tumor classification, prognostic stratification and ameliorating the management of patients based on a personalized approach.
Identifiants
pubmed: 33641005
doi: 10.1007/s11864-021-00825-4
pii: 10.1007/s11864-021-00825-4
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM